Compare CRTO & WVE Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | CRTO | WVE |
|---|---|---|
| Founded | 2005 | 2012 |
| Country | France | Singapore |
| Employees | N/A | N/A |
| Industry | Advertising | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.1B | 1.2B |
| IPO Year | 2013 | 2015 |
| Metric | CRTO | WVE |
|---|---|---|
| Price | $20.40 | $18.54 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 9 | 12 |
| Target Price | ★ $38.67 | $19.08 |
| AVG Volume (30 Days) | 471.4K | ★ 9.2M |
| Earning Date | 10-29-2025 | 11-10-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 83.79 | N/A |
| EPS | ★ 3.00 | N/A |
| Revenue | ★ $1,956,800,000.00 | $109,230,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | $1.42 | $31.09 |
| P/E Ratio | $7.01 | ★ N/A |
| Revenue Growth | 0.53 | ★ 103.75 |
| 52 Week Low | $19.00 | $5.28 |
| 52 Week High | $47.27 | $19.60 |
| Indicator | CRTO | WVE |
|---|---|---|
| Relative Strength Index (RSI) | 49.13 | 88.69 |
| Support Level | $19.00 | $6.93 |
| Resistance Level | $21.48 | $7.78 |
| Average True Range (ATR) | 0.78 | 0.86 |
| MACD | 0.08 | 0.75 |
| Stochastic Oscillator | 56.45 | 91.86 |
Criteo SA is an ad-tech company in the digital advertising market. Its technology, allows retailer advertisers to launch multichannel and cross-device marketing campaigns in real time. With real-time return on investment analysis of the ads, the firm's clients can adjust their marketing strategies dynamically. It has two reportable segments: Retail Media and Performance Media. The firm also provides technology allowing retailers to effectively manage their ad inventories and improve yield optimization.
WAVE Life Sciences Ltd is a clinical-stage biotechnology company focused on unlocking the broad potential of RNA medicines also known as oligonucleotides, targeting ribonucleic acid (RNA), to transform human health. RNA medicines platform, PRISM, combines multiple modalities, chemistry innovation, and deep insights into human genetics to deliver scientific breakthroughs that treat both rare and prevalent disorders. Its toolkit of RNA-targeting modalities includes RNA editing, antisense silencing, and RNA interference, providing capabilities for designing and sustainably delivering candidates that optimally address disease biology. Its programs are for rare and prevalent diseases, including alpha-1 antitrypsin deficiency, obesity, Duchenne muscular dystrophy, and Huntington's disease.